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Frequency and Spectrum of Mutations at
Codons 12 and 13 of the C-K-ras Gene in
Human Tumors
by Gabriel Capella,* Sandra Cronauer-Mitra,* Miguel Angel
Peinado,* and Manuel Perucho*
The frequency of point mutations at codons 12 and 13 of the c-K-ras gene has been determined in a
panel of more than 400 human tumors. Mutant c-K-ras genes were detected in about 75% of adenocarci-
nomas of the pancreas (n = 84); 40% of adenomas (n = 72) and carcinomas (n = 244) of the colon and
rectum; 30% ofcarcinomas ofthe bile duct (n = 19); 25% ofcarcinomas ofthe lung (n = 92), and in lower
frequency in other carcinomas, including liver, stomach, and kidney. No mutations were found in car-
cinomas of the breast, prostate, esophagus, and gall bladder, among others. Comparative analysis of the
spectrum ofmutations show that while G to A transitions were the most frequent mutations in pancreatic
and colo-rectal tumors, G to T transversions were more prevalent in lung carcinomas. The aspartic acid
mutation at codon 13 (GGC -* GAC) was relatively frequent in colo-rectal tumors but rare in pancreatic
and lung carcinomas. The differences in the mutation spectrum of the c-K-ras gene in cancers of the
gastrointestinal and respiratory tracts are suggestive of differential exposure to genotoxic agents.
Introduction
The theory that neoplastic transformation is the re-
sult ofcombinations ofgenetic alterations that occur in
a single cell during the life of an individual and that
accumulate in a sequential manner is becoming gener-
ally accepted as the experimental evidence is increasing
rapidly (1). According to this theory, the balanced in-
terplaybetweenproto-oncogenes andtumor-suppressor
genes that control cell growth and differentiation is dis-
ruptedbyaccumulative genetic damage and, despitethe
fail-safe mechanisms provided by the evolution by nat-
ural selection, neoplastic transformation occurs. Onco-
genes are the activated forms of cellular proto-onco-
genes, whose products are involved in cell growth or
differentiation (2,3). Tumor-suppressor genes are those
playing a negative regulatory role in these processes
(4,5). The recent development of methods for the de-
tection and characterization of genetic alterations re-
sponsible for oncogene activation andtumor-suppressor
gene inactivation is providing new insights in the un-
derstanding ofthemoleculargenetics ofmalignancy and
is finding applications for cancer diagnosis at the mo-
lecular genetic level (6,7). Single base substitutions are
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the most frequent ofthese genetic alterations, both ac-
tivating the malignant potential ofproto-oncogenes and
disrupting the inhibitory function of tumor-suppressor
genes (2-5,8).
Theoncogenesmostoftenassociatedwithhumanneo-
plasia are three members of the ras gene superfamily:
c-H-ras, c-K-ras, and N-ras. The ras gene products,
p2lras, are membrane-bound proteins which possess
guanine nucleotide bindingand hydrolytic activities and
appeartobeinvolvedinthesignaltransductionpathway
of cell growth and differentiation of mammalian cells
(9). The discovery of a cellular protein, termed GAP
(GTPase activating protein), which stimulates the in-
trinsic GTPase activity ofras proteins (10), is substan-
tially contributing to our understanding of the mecha-
nisms ofrasfunctionandactivation. GAPinteractswith
ras, stimulating its GTPase activity and inhibiting ras
function (11). Phosphorylation by tyrosine protein kin-
ases, such as membrane receptors (i.e., epidermal
growth factor and platelet-derived growth factor
[PDGF]) and other oncogene proteins like p60 src
(12,13) may in turn regulate GAP. Whether or not GAP
is also the effector for ras or only acts upstream in the
ras pathwayis not clear. In any case, these studies may
provide a link in the signal transduction pathway be-
tween ras proteins and extracellular signals via their
receptors and GAP. How the signal is finally transmit-
ted to the nucleus, leading to DNAreplication, remains
to be determined. However, it is clear that other key16CAPELLA ET AL.
components in the control of cell replication and there-
fore in the potential for malignant transformation are
nuclear transcriptional factors with oncogenic activities
(i.e., myc,fos,jun) and alsotheproducts ofthe recently
characterized tumor-suppressor genes, the retinoblas-
toma susceptibility (Rb) and the p53 genes. The impor-
tance of the last class of genes is clearly demonstrated
by the fact that DNA tumor viruses (SV40, adeno, and
papilloma) exert their oncogenic effects via interaction
(and presumably inactivation) of these two tumor-sup-
pressor gene products with their corresponding onco-
genic proteins (T antigen, ElA and E1B, and E6 and
E7 gene products) (4).
The oncogenic potential of ras genes is activated by
single base substitutions, usually in codons 12, 13, or
61 (14). The mechanism by which single amino acid sub-
stitutionsincriticaldomainsresultindramaticincreases
intheoncogenicpotential ofras proteinsinvolve diverse
types of disruption of protein structure, all leading to
an increase in their active, GTP-bound state. In animal
model systems, tumors induced by a variety of carcin-
ogensreproducibly contain single pointmutations inthe
ras oncogenes (9,15). These results provide persuasive
evidence to the notion that the carcinogen mutates its
target, the ras proto-oncogene, activating its oncogenic
potential and initiating the tumorigenesis process. In
contrast, examples ofcomparable high incidence ofras
mutations associated with a specific type ofhuman can-
cer had not been reported. Consequently, the etiology
ofthese mutations and their role in human carcinogen-
esis have remained uncertain. We will summarize here
the results of our analysis on the frequency of point
mutations at codons 12 and 13 of the c-K-ras gene in
human tumors and the comparative analysis ofthe spec-
trum of mutations at these positions in pancreatic and
lung carcinomas and in colo-rectal adenomas and car-
cinomas.
Methods
The recent development of the polymerase chain re-
action (PCR), a simple technique for the in vitro am-
plification ofDNA sequences (16,17), has facilitated the
detection ofras mutations and othergenetic alterations
andtheanalysis oftheirrole intumorigenesis (7). Single
base substitutions can be readily detected by a number
of methods, including allelic-specific oligonucleotide
(ASO) hybridization (18,19), RNAse A mismatch cleav-
age ofthe DNA-RNAhybrids (20,21), orDNAsequenc-
ing, either directly (22,23) or after cloning the PCR
products in plasmids (24,25). Thegeneration ordestruc-
tion of restriction endonuclease sites (RFLP) by point
mutations also allows their rapid detection after the
genomic sequences have been amplified by the PCR
(26,27).
The great sensitivity of the PCR allows the amplifi-
cation of DNA sequences from very small amounts of
tissue such as tumorbiopsies. Inaddition, thetechnique
can use formalin-fixed, paraffin-embedded tissue spec-
imens (28) obtained after surgical resections and also
from autopsies (29). This facilitates the analysis ofsome
types of tumors for which surgical specimens are diffi-
cult to obtain due to their low incidence orto their poor
prognosis. For instance, fresh specimens of pancreatic
adenocarcinoma are difficult to collect, as surgical re-
section is often not attempted due to the morbidity of
the procedure and its poor therapeutic outcome. For-
malin-fixed specimens ofpancreatic adenocarcinoma (or
any tumor) are more readily available, since they are
stored for years in paraffin blocks by most pathology
departments. We developed aprocedurethatallowsthe
detection of single point mutations in the c-K-ras gene
present in a single 5 to 10 ,um section of the formalin-
fixed, paraffin-embedded tumor tissue (20).
To detect mutations in the c-K-ras gene, we initially
used the RNAse A mismatach cleavage method either
alone orincombination withthePCR (20,21,30)because
the method permits the simultaneous analysis of mul-
tiple samples and is highly sensitive. However, RNAse
A mismatch cleavages does not characterize the molec-
ular nature of the mutation. More recently, we have
used the artificial RFLP approach originally described
by Kumar and Barbacid (26), as modified by Jiang et
al. (27) to detect and characterize point mutations at
codons 12 and 13 ofthe c-K-ras gene. We will describe
here our procedure to detect any mutation at codon 12
(GGT) as an example ofthe strategy (Fig. 1). Replace-
ment of the second G at codon 13 (GGC) by an A, by
using a single base mismatched primer generates an
HphI site (GGTGA) that is destroyed by any mutation
at any of the two Gs of codon 12. Mutations of the
following T and G are not considered, because they
would be erased by the PCR primers. Mutations are
detected by the presence of DNA fragments not di-
gested by the enzyme. Another HphI site introduced
by the upstream primer is used as internal control to
test the completion of digestion and the efficiency of
incorporation of the mutant nucleotide.
Bythisapproach, mutantallelescanbedetectedwhen
present in about 5 and 1% ofthe total by staining with
ethidium bromide and by Southern blots, respectively.
The sensitivity of this method is initially high because
the mutationis detected bythe presence ofnondigested
DNA fragments, which includes not only mutant se-
quences, but also hybrid molecules between wild-type
and mutant DNA strands. This is likely to occur during
the melting and annealing steps of the last cycles, es-
pecially iftheir number is high in the PCR experiment.
Conversely, the sensitivity ofmutation detectionis con-
siderably decreased when the mutant allele is digested
with an endonuclease, but the wild-type allele is not.
By using other RFLPs at codon 12, either natural or
artificially introduced by the use of other mutant
primers, all sixdifferent aminoacid substitutions atthis
position can be readily characterized without the use of
radioactive isotopes. Mutations canbe also detected and
characterized in DNA sequences PCR-amplified from
single 5 to 10 ,um sections of paraffin blocks by the
artificial RFLP method as described before (Fig. 1).
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FIGURE 1. Detection of c-K-ras mutations in human tumors by
RFLP ofPCR amplified DNA. DNA sequences ofthe first coding
exon of the c-K-ras gene were amplified using the primers 5'
GAGAAGCTTATGTGTGACATGTCTA 3' and 5' GAAG-
GATCCTGCACCAGTAATATGCA 3' for 25 cycles (50°C for 35
sec; 72°C for 1 min and 25 sec; 94°C for 1 min) (PCR 1). One
microliter of the PCR product was reamplified (PCR 2) with
nested, mutant amplimers 5' CCTGGTGAAAATGACTGAAT 3'
and 5' AGGCACTCTTGCCTACGTCA 3' for other 35 cycles (50°C
for 15 sec; 72°C for 30 sec; 94°C for 15 sec), yielding a 65 bp DNA
fragment. After digestion with HphI following manufacturer's di-
rections, the samples were analyzed in a 12% acrylamide native
gel and stained with ethydium bromide. (M) Hae III-digested
OX179 fragments; (870) DNA obtained from normal colonic mu-
cosa; (U) undigested PCR product; and (C) DNA sample after
digestion. (PANC-1 and AsPC-1) human pancreatic carcinoma cell
lines used as positive controls for c-K-ras codon 12 aspartic acid
mutations. PANC-1 isheterozygous forthemutation, whileAsPC-
1 contains only the mutant c-K-ras allele. (6 and 34) Colorectal
adenoma and carcinoma, respectively. (FNA 7 and 55) Fine needle
aspirates from pancreatic adenocarcinomas. In these four cases
DNA was amplified from formalin-fixed paraffin-embedded tis-
sues.
The technical details ofthis methodology are described
in Shibata et al. (31).
Results
Frequency of c-K-ras Mutations in Human
Tumors
The results of our studies on the involvement ofpoint
mutations in the c-K-ras gene in various types ofhuman
tumors, mainly carcinomas, are summarized in Table 1.
Table 1. Frequency of point mutations at codons 12 and 13 of
the c-K-ras gene in human tumors.
Tumor type Positivea Total Percent
Pancreasb 63 84 75.0
Colon and rectum
Adenomas 28 72 38.8
Carcinomasc 98 244 40.1
Bile ductd 6 19 31.5
Lunge 23 92 25.0
Liver 1 14 7.1
Stomach 1 14 7.1
Kidney 1 14 7.1
Other' 0 57 0.0
'All at codon 12 but one pancreatic carcinoma, 1 extrahepatic bile
duct carcinoma, 1 lung carcinoma, and 26 colo-rectal tumors (12 ad-
enomas and 14 carcinomas) with mutations at codon 13.
bPrimary and metastatic (55 positive of72 analyzed) and tumor cell
lines (8/12).
cPrimary and metastatic carcinomas (89/232) and tumor cell lines
(9/12).
dCholangiocarcinomas (2/5), periampullary (3/12), and extrahepatic
bile duct (1/2) carcinomas.
ePrimary carcinomas (17/85) and tumor cell lines (6/7).
'Carcinomas ofthebreast (12), prostate (10), thyroid (8), esophagus
(5), gallbladder (5), endometrium (4), and others (13). In addition, 20
melanomas and 5 tumors of the endocrine pancreas were found neg-
ative.
The frequency ofc-K-ras genes with mutations atcodon
12 or 13 fluctuates considerably depending on the type
of tumor. The most striking observation is the high
incidence ofc-K-rasmutationsinpancreaticcarcinomas.
This high frequency appearstobe specificforthistumor
because it is significantly lower in cholangiocarcinomas,
extrahepatic bile duct carcinomas, and carcinomas of
the ampulla of Vater and absent or much lower in gall
bladder, hepatocellular, gastric and esophageal carci-
nomas, and tumors of the endocrine pancreas (21,31).
Because the pathway for malignancy for the majority
ofhuman pancreatic adenocarcinomas involves the mu-
tation at codon 12 ofthe c-K-ras gene, the presence of
the mutation can serve as a molecular genetic marker
for this malignancy. Aspirates of pancreatic adenocar-
cinoma, obtained by fine needle (FNA), were analyzed
for c-K-ras mutations (32). The results ofthis combined
molecular genetic and cytologic approach indicate that
inselectedcases, thedetectionofmutatedc-K-rasgenes
allowed a correct diagnosis of malignant disease, al-
though this diagnosis was suspected but notestablished
by cytology.
We have also analyzed about 300 colo-rectal tumors
for the presence of mutations in the first coding exon
of the c-K-ras gene. In our initial studies using the
RNAse A mismatch cleavage method (33), we detected
about 40% ofcolo-rectal adenomas and carcinomas pos-
itive for mutations at codon 12 (21,30). However, mu-
tations at codon 13 ofthe c-K-ras gene, exclusively the
aspartic acid (ASP13) substitution (GGC -* GAC), were
reported by Vogelstein et al. (19). We know now that
the ASP13mutations inthec-K-ras sequences generate
single base mismatches in the RNA:RNA hybrids that
are notrecognizedbytheenzyme. UsingRFLPanalysis
with c-K-ras sequences amplified by the PCR, we have
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confirmed these findings (19) and have found that about
10% of colo-rectal tumors contain c-K-ras genes with
the ASP13 mutation.
Our results show that the incidence of c-K-ras mu-
tations increases during colo-rectal tumorigenesis and
correlates with tumors conserving a well-differentiated
phenotype (21,30). On the other hand, no correlations
were foundwiththe sex, race, oranatomicallocalization
ofthe tumors (21,30,34). Follow-up analysis ofthe colo-
rectal cancer patients is underway to determine the
possible value for cancer prognosis of the presence or
absence ofmutated c-K ras genes (35) or differences in
the amino acid substitutions in the positive cases (see
below).
Mutation Spectrum of c-K-ras in Human
Carcinomas
Analysis ofthe specific nucleotide changes at codons
12 and 13 of the c-K-ras gene in human carcinomas
reveals a marked heterogeneity, although some muta-
tions are more frequent than others. Differences in the
spectrum ofmutations can be also observed depending
on the type of tumor (Fig. 2). In both colo-rectal and
pancreatic carcinomas, the most prevalent mutations
involve G to A transitions. The most characteristic dif-
ference between the mutations occurring in these two
different tumors is the aspartic acid substitution at co-
don 13 (ASP13). This mutation is relatively frequent in
colo-rectal tumors, but very rare in pancreatic adeno-
carcinomas and also in lungcarcinomas. In this context,
it is remarkable that c-K-ras genes with the ASP13
mutation are foundpredominantly inbenigntumors (ad-
enomas) and in carcinomas of older colo-rectal cancer
patients compared with those containing other muta-
tions or with tumors without mutant c-K-ras genes (M.
Perucho et al., manuscript in preparation).
In contrast with the prevalence ofG to A transitions
in these gastrointestinal tumors, in carcinomas of the
lung, the G to T transversions are more frequent. This
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FIGURE 2. Spectrum of c-K-ras mutations at codon 12 and 13 in
human carcinomas. The total number of mutations characterized
is indicated inside the sectors. One hundred thirteen mutations
have been characterized in colo-rectal tumors (27 in adenomas and
86 in adenocarcinomas). No tumor cell lines have been included.
Fifty-one mutations have been characterized in human pancreatic
carcinomas (44 in tumors and 7 in cell lines); 23 mutations have
been characterized in human lung carcinomas (17 in tumors and 6
in tumor cell lines). Only the aspartic acid mutation (GAC) was
found at codon 13.
observation is in agreement with the results of Roden-
huis et al. (36). This observation is also in consonance
with other studies of lung adenomas and carcinomas
induced by some chemical carcinogens in animal model
systems (23).
Discussion
Our finding that a vast majority ofhuman pancreatic
carcinomas contain point mutations at codon 12 of the
c-K-ras gene suggests that these mutations are impor-
tant events in the genesis of cancer of the pancreas.
However, the timing of activation of the c-K-ras gene
in pancreatic carcinoma, as well as the role it plays in
the tumorigenesis process, remains to be determined.
Because thereisasignificantproportion ofthesetumors
that do not harbor ras mutations (21), pancreatic ad-
enocarcinoma might also develop through a pathway of
genetic alterations that does not involve ras somatic
mutational activation. Moreover, because the point mu-
tationinthe c-K-ras gene cannotbe sufficienttoaccount
for this aggressive neoplasia, other genetic alterations
must be also involved in pancreatic oncogenesis. Pre-
liminary results indicate that inactivation of the p53
gene is involved in the genesis ofpancreatic cancer. We
have detected hemizygous mutations in conserved po-
sitions of the gene coding region in most of the tumor
cell lines examined and in some primary tumors (J.
Schaeffer et al., manuscript in preparation).
The disruption ofthe balanced interplay between on-
cogenes and tumor-suppressor genes is clearly exem-
plified in colo-rectal tumorigenesis. It is believed that
a majority of carcinomas from the colon and rectum
develop through a previous benign stage, the adenoma
or adenomatous polyp (37,38). Work by Vogelstein's
group has convincingly shown that colo-rectal tumori-
genesis is acomplex and accumulative processinvolving
the inactivation ofat leasttwotumor-suppressor genes,
p53 and DCC (deleted in colon cancer). These genes
encode a nucleoprotein and a membrane protein with
similarities to the adhesins and other membrane gly-
coproteins, respectively (8,39,40). Together with the
gene located in chromosome 5 (41), segregating with
the syndrome offamilial polyposis, the process of colo-
rectal oncogenesis may involve inactivation of at least
three loci with up to six total genetic alterations.
The finding that nearly one-halfofcolo-rectal tumors
contain mutated c-K-ras genes (18,19,21,30) also indi-
cates that activation of this dominant-acting oncogene
must be also an important event in the process. More-
over, accumulative alterations leading to an increase in
the ratio of mutant/normal ras allele also occur often
duringtumorprogression (21). Wehave alsoshownthat
moderate increases in the copy number and transcript
levels of a mutant human c-K-ras gene have profound
consequences in the manifestation of the malignant
phenotype both invitro and invivo (42). Therefore, the
accumulative genetic alterations occurring in the same
single locus, the c-K-ras gene, add anotherlevelofcom-
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Table 2. Relative frequency of G to A transitions at codons 12 and 13 of ras genes in human tumors.a
Sequence Codon 12 Codon 13
Gene 12 13 AGT (SER) GAT (ASP) AGT (SER) GAT (ASP) Restb Total (%)
K-ras GGT GGC 16 154 0 45 228 443 (71.3)
N-ras GGT GGT 10 33 1c 11 114 167 (26.9)
H-ras GGC GGT 0 6 0 0 5 11 (1.8)
Total 26 193 1 56 347 621
% 4.1 31.0 0.1 9.0 55.8
aCompiled from Ellis et al. (13), Shibata et al. (31), Nagata et al. (50), Tada et al. (51), and our unpublished results..
bRest of mutations at codons 12 and 13 and all mutations at codon 61.
cDetected in a multiple myeloma that also contained a GCT(ALA) mutation at codon 12 (49).
Table 3. Aspartic acid mutations at codon 12 of ras genes in carcinogen-induced tumors.
Tumor' Carcinogenb Gene Incidence (%) Reference
Lung adenoma Spontaneous K 1/5 (20) (23)
Lung carcinoma Spontaneous K 2/5 (40) (25)
Lung adenoma MNU K 15/15 (100) (25)
Lung adenoma BP K 4/14 (28) (23)
Thymoma MNU K 22/55 (40) (46)
Thymoma X-rays K 7/37 (19) (46)
Thymoma MNU N 1/55 (2) (46)
Thymoma X-rays N 1/37 (3) (46)
Skin papilloma MNU H 5/12 (41) (52)
Skin papilloma MNNG H 11/15 (73) (52)
Skin carcinoma MNNG H 2/13 (15) (56)
Lung carcinoma TNM K 9/9 (100) (53)
Lung carcinoma TNM K 14/14 (100) (53)
Mammary carcinoma MNU H 61/61 (100) (54)
Kidney mesenchimal MNU K 31/35 (88) (54)
'All tumors are mouse tumors but the last three, which are in rats.
bMNU, methylnitrosourea; BP, benzo[a]pyrene; MNNG, methylnitrosoguanidine; TNM, tetranitromethane.
plexity to the spectrum of genetic alterations involved
in human colo-rectal tumorigenesis.
Moreover, the diversity of point mutations occurring
both in the ras oncogenes and in the p53 tumor-sup-
pressor gene (43,44) could have influence on tumor be-
havior. Of the mutations occurring at codons 12 and 13
of ras genes, the G to A transitions resulting in the
replacement of glycine by aspartic acid are the most
remarkable because of their relatively high incidence.
Table 2 summarizes the frequency of point mutations
inthe three ras genes found in human tumors. Although
this is not a comprehensive list of all mutations de-
scribed in the literature, it is sufficient to give a pan-
oramic view of the relative frequencies of different ras
mutations. It is clear that the most prevalent activated
ras gene is the c-K-ras and that nearly one-half of all
ras mutations are G to A transitions at codons 12 and
13. However, while the serine mutation at codon 13
(SER13) has been described only once (and in a multiple
myeloma containing an alanine at codon 12 [ALA12]
mutation), the aspartic acid mutation at codon 12
(ASP12) is more than twice as frequent as the two re-
maining mutations together: the serine mutation at co-
don 12 (SER12, AGT) and the aspartic acid mutation at
codon 13 (ASP13, GAC). This makes the G to A tran-
sition at the second position ofcodon 12 the single most
frequent ras mutation found in human tumors, com-
posingabout 30% ofthe total. The same Gto A mutation
at codon 13, although significant in its overall preva-
lence, is relatively much less frequent.
A similar situation is probably also true in the field
ofanimal carcinogen-induced tumormodel systems. De-
spite evident specificities in the association between
some carcinogens and the type of induced mutations
(45), the same G to A transition at the second position
of codon 12 of each of the three ras genes is also pre-
dominantly found in tumors, spontaneous or induced,
in rats and mice with a wide sample ofcarcinogens and
carcinogenic treatments. In contrast, we have found
only one report of ASP13 mutations, in a thymoma in-
duced inmice withmethylnitrosourea(46). Table 3 sum-
marizes anincomplete surveyoftheanimaltumormodel
system literature.
The heterogeneity in the spectrum of c-K-ras muta-
tions found in human carcinomas is not consonant with
the interpretation that these mutations are caused by
specific, defined carcinogens. It seems more likely that
they are caused by multiple and diverse mutagens, or
by spontaneous errors of the DNA replicative machin-
ery, or both. However, the differences in the mutation
spectrum between carcinomas of the gastrointestinal
and respiratory tracts point to broad but significant eti-
ological differences, perhaps due to differential expo-
sure to genotoxic agents: dietary in the first and air-
borne in the second. The characterization of the ras
mutation spectrum in different human carcinomas pro-
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vides a molecular epidemiological approach that could
shedsomelightontheiretiologies. Forinstance, itcould
direct the search for carcinogens present in the diet or
in cigarette smoke. The similarities in the spectra of
ras mutations found in lung tumors and those induced
byaromatic hydrocarbons such as benzopyrene (47) and
in gastrointestinal tumors with those induced by alkyl-
ating agents such as methylnitrosourea (48) are cer-
tainly very suggestive.
This work was supported by grant CA38579 from the National
Cancer Institute. G.C. is a fellow from the Spanish Ministry of Sci-
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